SCHEMBL23733975

SCHEMBL23733975

CSC(C)OC(=O)N1CCC(O)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.43
DPP7 Q9UHL4 2/20 0.37
HSD11B1 P28845 1/20 0.33
CYP3A4 P08684 4/20 0.33
HRH3 Q9Y5N1 1/20 0.32
PDE4B Q07343 1/20 0.32
LIPE Q05469 1/20 0.31
CTSK P43235 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
CYP2D6 P10635 2/20 0.30
SLC6A2 P23975 2/20 0.30
SLC6A4 P31645 2/20 0.30
SLC6A3 Q01959 2/20 0.30
KCNH2 Q12809 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609550 0.83 DPP4 (0.47) DPP4DPP7HSD11B1PDE4B
SCHEMBL12282871 0.83 DPP4 (0.47) DPP4DPP7HSD11B1PDE4B
SCHEMBL13752388 0.77 DPP4 (0.54) DPP4DPP7HSD11B1CYP3A4CTSK
SCHEMBL6484170 0.73 CHRNB2 (0.46) DPP4DPP7PDE4B
SCHEMBL3854429 0.73 CHRNB2 (0.46) DPP4DPP7PDE4B
SCHEMBL1942044 0.73 CHRNB2 (0.46) DPP4DPP7PDE4B
SCHEMBL21808048 0.73 DPP4 (0.41) DPP4DPP7HSD11B1NPC1RAB9A
SCHEMBL4595765 0.72 DPP4 (0.48) DPP4DPP7HSD11B1MEN1KMT2A
SCHEMBL287966 0.72 GPR119 (0.44) DPP4PDE4BLIPENPC1RAB9A
SCHEMBL701943 0.70 GAA (0.56) DPP4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084817-B2 Farnesoid X receptor agonists and uses thereof METACRINE, INC. (US) 2021-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084817-B2 Farnesoid X receptor agonists and uses thereof NR1H4, NR1H2, NR1H3 DPP4 954/4885DPP7 1036/4885HSD11B1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.